Announcements Trials
Browse Landscape

Phase

Phase 2 95Phase 3 44Phase 1 37Phase 1/2 23Phase 2/3 5Phase 4 4Phase NA 2Phase EARLY_PHASE1 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4

Interventions

Dexamethasone 11Lenalidomide 10Bortezomib 9Zoledronic Acid 8ixazomib 4daratumumab 4Melphalan 4tocilizumab 3Thalidomide 3Cyclophosphamide 3pomalidomide 2carfilzomib 2Prednisone 2Kyphoplasty 2Filgrastim 2Doxorubicin 2Calcium Dobesilate 2zanubrutinib 1talquetamab 1pegylated granulocyte colony-stimulating factor 1montelukast 1isatuximab 1ibrutinib 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1apixaban 1Vaccination 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × Multiple Myeloma × daratumumab × Clear all
NCT03829371 2025-12-03

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

University of Turin, Italy

Phase 4 Active not recruiting
450 enrolled
Plasma cell

Multiple Myeloma

NCT05511428 2025-11-21

Home Based Daratumumab Administration for Patients With Multiple Myeloma

Thomas Jefferson University

Phase 4 Completed
20 enrolled 38 charts
Plasma cell

Multiple Myeloma

NCT06409702 2025-06-12

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

The First Affiliated Hospital of Soochow University

Phase 4 Recruiting
59 enrolled
Plasma cell

Multiple Myeloma

NCT03768960 2025-02-03

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Johnson & Johnson Private Limited

Phase 4 Completed
150 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡